Search Results - "DiSimone, C."

796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111 by Makker, V., Taylor, M.H., Aghajanian, C., Cohn, A.L., Brose, M.S., DiSimone, C., Cao, A., Suttner, L., Loboda, A., Cristescu, R., Jelinic, P., Snyder, A., Nebozhyn, M., Lunceford, J., Orlowski, R., Dutta, L., Matsui, J., Dutcus, C., Minoshima, Y., Messing, M.

Get full text

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial by Makker, V., Rasco, D., Vogelzang, N., Brose, M., Cohn, A., Mier, J., DiSimone, C., Hyman, D.M., Stepan, D., Dutcus, C., Schmidt, E., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C., Taylor, M.

Get full text

994O - Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

“…LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a cohort of patients…”
Get full text

Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis by Lee, C.-H., Shah, A.Y., Makker, V., Taylor, M.H., Shaffer, D., Hsieh, J.J., Cohn, A.L., DiSimone, C., Marin, A Pinto, Rasco, D.W., Ribe, S.G., Richards, D.A., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Perini, R.F., Motzer, R.J.

Get full text

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

Get full text

1187PD - Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis by Lee, C.-H., Shah, A.Y., Makker, V., Taylor, M.H., Shaffer, D., Hsieh, J.J., Cohn, A.L., DiSimone, C., Marin, A Pinto, Rasco, D.W., Ribe, S.G., Richards, D.A., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Perini, R.F., Motzer, R.J.

“…Lenvatinib (LEN) is a multikinase VEGFR inhibitor approved for use in combination with everolimus to treat advanced RCC after prior VEGF-targeted therapy…”
Get full text

1187PDPhase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis by Lee, C-H, Shah, A Y, Makker, V, Taylor, M H, Shaffer, D, Hsieh, J J, Cohn, A L, DiSimone, C, Marin, A Pinto, Rasco, D W, Ribe, S G, Richards, D A, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Perini, R F, Motzer, R J

“…Abstract Background Lenvatinib (LEN) is a multikinase VEGFR inhibitor approved for use in combination with everolimus to treat advanced RCC after prior…”
Get full text

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V, Taylor, M H, Aghajanian, C, Oaknin, A, Mier, J, Cohn, A L, Marin, M Romeo, Lorenzo, R Bratos, Brose, M S, DiSimone, C, Messing, M J, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Orlowski, R J, Sachdev, P, Shumaker, R, Herraez, A Casado

“…Abstract Background LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a…”
Get full text

The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor by Gallaher, W R, DiSimone, C, Buchmeier, M J

“…Recent studies of viral entry proteins from influenza, measles, human immunodeficiency virus, type 1 (HIV-1), and Ebola virus have shown, first with molecular…”
Get full text

Kinetics and pH Dependence of Acid-Induced Structural Changes in the Lymphocytic Choriomeningitis Virus Glycoprotein Complex by Di Simone, Christopher, Buchmeier, Michael J.

“…The NBD-PE/Rd-PE fluorescent membrane fusion assay was used to measure the pH dependence and kinetics of the fusion activity of lymphocytic choriomeningitis…”
Get full text

Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike by Di Simone, C, Zandonatti, M A, Buchmeier, M J

“…Membrane fusion activity of the glycoprotein (GP) complex of LCMV was determined using the R18 fluorescent dequenching assay. Utilization of an endosomal entry…”
Get more information

Membrane fusion of mumps virus with ghost erythrocytes and CV-1 cells by Di Simone, C, Baldeschwieler, J D

“…The octadecyl rhodamine (R18) fluorescent dequenching assay was used to examine membrane fusion between mumps virus and mammalian cells. Rapid fluorescent…”
Get more information